Literature DB >> 29285660

Effect of Blood Phenylalanine Levels on Oxidative Stress in Classical Phenylketonuric Patients.

Burcu Kumru1, Davut Sinan Kaplan2, Burcu Oztürk Hismi3, Hakim Celik4.   

Abstract

Mental retardation, which occurs in phenylketonuric patients, is associated with increased levels of phenylalanine, increased oxidative stress, and an imbalance of amino acids in the brain. Recent studies have shown that oxidative stress plays a role in the pathogenesis of phenylketonuria. In this work, we aimed to compare the influence of blood phenylalanine levels on oxidative stress parameters in phenylketonuric patients who divided patients into groups according to blood Phe levels during follow-up visits and compared these groups with healthy controls. Results showed significant differences in glutathione peroxidase (GSHPx), coenzyme Q10 (Q10), Q10/cholesterol, and L-carnitine levels in phenylketonuria patients and the control group. GSHPx, Q10, and Q10/cholesterol levels were significantly lower in poor adherence patients than in the control groups. L-carnitine levels were significantly increased in good adherence patients than poor adherence patients and decreased in poor adherence patients than healthy controls. No correlations were observed between phenylalanine and L-carnitine concentrations in poor adherence group. No significant differences were observed in paraoxonase 1 (PON1), total antioxidant status (TAS), total oxidant status (TOS) and oxidative stress index (OSI) levels. As a result, in this work, poor adherence patients are prone to oxidative stress. Although the patients may have the same diagnosis, patients have different clinical characteristics and different prognosis. Antioxidants can be used as an adjuvant therapy in order to avoid neurological damage in these patients.

Entities:  

Keywords:  Antioxidant; Neuroprotection; Oxidative stress; Phenylketonuria

Mesh:

Substances:

Year:  2017        PMID: 29285660     DOI: 10.1007/s10571-017-0573-2

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  33 in total

1.  Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet.

Authors:  K H Schulpis; A Bartzeliotou; S Tsakiris; A Gounaris; I Papassotiriou
Journal:  Eur J Clin Nutr       Date:  2007-01-03       Impact factor: 4.016

Review 2.  Oxidative stress in phenylketonuria: future directions.

Authors:  Júlio César Rocha; Maria João Martins
Journal:  J Inherit Metab Dis       Date:  2011-11-25       Impact factor: 4.982

3.  Experimental hyperphenylalaninemia provokes oxidative stress in rat brain.

Authors:  Martine E Kienzle Hagen; Carolina D Pederzolli; Angela M Sgaravatti; Raquel Bridi; Moacir Wajner; Clóvis M D Wannmacher; Angela T S Wyse; Carlos S Dutra-Filho
Journal:  Biochim Biophys Acta       Date:  2002-04-24

4.  Plasma phenylalanine is associated with decreased serum ubiquinone-10 concentrations in phenylketonuria.

Authors:  R Artuch; C Colomé; M A Vilaseca; C Sierra; F J Cambra; N Lambruschini; J Campistol
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

5.  Oxidative status and serum PON1 activity in beta-thalassemia minor.

Authors:  Sahbettin Selek; Mehmet Aslan; Mehmet Horoz; Mustafa Gur; Ozcan Erel
Journal:  Clin Biochem       Date:  2007-01-13       Impact factor: 3.281

6.  L-carnitine protects gastric mucosa by decreasing ischemia-reperfusion induced lipid peroxidation.

Authors:  N Derin; V N Izgut-Uysal; A Agac; Y Aliciguzel; N Demir
Journal:  J Physiol Pharmacol       Date:  2004-09       Impact factor: 3.011

7.  A longitudinal study of antioxidant status in phenylketonuric patients.

Authors:  Rafael Artuch; Catrina Colomé; Cristina Sierra; Nuria Brandi; Nilo Lambruschini; Jaume Campistol; Dolores Ugarte; Maria A Vilaseca
Journal:  Clin Biochem       Date:  2004-03       Impact factor: 3.281

8.  Oxidative stress in plasma from maple syrup urine disease patients during treatment.

Authors:  Alethéa G Barschak; Angela Sitta; Marion Deon; Amanda T Barden; Carlos S Dutra-Filho; Moacir Wajner; Carmen R Vargas
Journal:  Metab Brain Dis       Date:  2007-11-17       Impact factor: 3.584

Review 9.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

10.  Antioxidant status in hyperphenylalaninemia.

Authors:  C Sierra; M A Vilaseca; D Moyano; N Brandi; J Campistol; N Lambruschini; F J Cambra; R Deulofeu; A Mira
Journal:  Clin Chim Acta       Date:  1998-08-10       Impact factor: 3.786

View more
  3 in total

Review 1.  Oxidative stress in phenylketonuria-evidence from human studies and animal models, and possible implications for redox signaling.

Authors:  Vanessa Trindade Bortoluzzi; Carlos Severo Dutra Filho; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2021-02-13       Impact factor: 3.584

Review 2.  Impact of pregnancy on inborn errors of metabolism.

Authors:  Gisela Wilcox
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

3.  CRISPR/Cas9 generated knockout mice lacking phenylalanine hydroxylase protein as a novel preclinical model for human phenylketonuria.

Authors:  Kuldeep Singh; Cathleen S Cornell; Robert Jackson; Mostafa Kabiri; Michael Phipps; Mitul Desai; Robert Fogle; Xiaoyou Ying; Gulbenk Anarat-Cappillino; Sarah Geller; Jennifer Johnson; Errin Roberts; Katie Malley; Tim Devlin; Matthew DeRiso; Patricia Berthelette; Yao V Zhang; Susan Ryan; Srinivas Rao; Beth L Thurberg; Dinesh S Bangari; Sirkka Kyostio-Moore
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.